bit.bio announces £40m Series C from M&G Investments to pioneer human cell programming technology

bit.bio develops human cell programming technology that produces consistent, scalable human cells for research, drug discovery and toxicology, helping pharmaceutical and biotech companies reduce reliance on animal testing and improve predictive accuracy.